Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 25

1.

Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.

O'Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, Carson P, Haass M, Hauptman PJ, Metra M, Oren RM, Patten R, Piña I, Roth S, Sackner-Bernstein JD, Traver B, Cook T, Gheorghiade M; Efficacy of Vasopressin Antagonism in heart Failure Outcome Study with Tolvaptan (EVEREST) investigators.

Am Heart J. 2010 May;159(5):841-849.e1. doi: 10.1016/j.ahj.2010.02.023. Erratum in: Am Heart J. 2012 May;163(5):900.

PMID:
20435194
2.

MERIT-HF mortality and morbidity data.

Hjalmarson A, Fagerberg B.

Basic Res Cardiol. 2000;95 Suppl 1:I98-103. Review.

PMID:
11192362
3.

Tolvaptan, an orally active vasopressin V(2)-receptor antagonist - pharmacology and clinical trials.

Miyazaki T, Fujiki H, Yamamura Y, Nakamura S, Mori T.

Cardiovasc Drug Rev. 2007 Spring;25(1):1-13. Review.

PMID:
17445084
4.

Vasopressin antagonists: Pharmacotherapy for the treatment of heart failure.

Reilly T, Schork MR.

Ann Pharmacother. 2010 Apr;44(4):680-7. doi: 10.1345/aph.1M660. Review.

PMID:
20332337
5.

A review of heart failure management in the elderly population.

Cheng JW, Nayar M.

Am J Geriatr Pharmacother. 2009 Oct;7(5):233-49. doi: 10.1016/j.amjopharm.2009.10.001. Review.

PMID:
19948300
6.

Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials.

Ezekowitz JA, McAlister FA.

Eur Heart J. 2009 Feb;30(4):469-77. doi: 10.1093/eurheartj/ehn543. Epub 2008 Dec 9. Review.

7.

A comparative analysis of the results from 4 trials of beta-blocker therapy for heart failure: BEST, CIBIS-II, MERIT-HF, and COPERNICUS.

Domanski MJ, Krause-Steinrauf H, Massie BM, Deedwania P, Follmann D, Kovar D, Murray D, Oren R, Rosenberg Y, Young J, Zile M, Eichhorn E; BEST Investigators.

J Card Fail. 2003 Oct;9(5):354-63. Review.

PMID:
14583895
8.

Medical therapy for acute decompensated heart failure: what recent clinical trials have taught us about diuretics and vasodilators.

Marti C, Cole R, Kalogeropoulos A, Georgiopoulou V, Butler J.

Curr Heart Fail Rep. 2012 Mar;9(1):1-7. doi: 10.1007/s11897-011-0072-6. Review.

PMID:
21874282
9.

Tolvaptan for the treatment of heart failure: a review of the literature.

Ambrosy A, Goldsmith SR, Gheorghiade M.

Expert Opin Pharmacother. 2011 Apr;12(6):961-76. doi: 10.1517/14656566.2011.567267. Epub 2011 Mar 15. Review.

PMID:
21401442
10.

The disconnect between phase II and phase III trials of drugs for heart failure.

Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J.

Nat Rev Cardiol. 2013 Feb;10(2):85-97. doi: 10.1038/nrcardio.2012.181. Epub 2013 Jan 8. Review.

PMID:
23296069
11.

Meta-analysis of cell therapy trials for patients with heart failure.

Fisher SA, Doree C, Mathur A, Martin-Rendon E.

Circ Res. 2015 Apr 10;116(8):1361-77. doi: 10.1161/CIRCRESAHA.116.304386. Epub 2015 Jan 28. Review.

PMID:
25632038
12.

Newest additions to heart failure treatment.

Orso F, Fabbri G, Baldasseroni S, Maggioni AP.

Expert Opin Pharmacother. 2014 Sep;15(13):1849-61. doi: 10.1517/14656566.2014.934812. Epub 2014 Jul 3. Review.

PMID:
24989872
13.

Current management and future directions for the treatment of patients hospitalized for heart failure with low blood pressure.

Gheorghiade M, Vaduganathan M, Ambrosy A, Böhm M, Campia U, Cleland JG, Fedele F, Fonarow GC, Maggioni AP, Mebazaa A, Mehra M, Metra M, Nodari S, Pang PS, Ponikowski P, Sabbah HN, Komajda M, Butler J.

Heart Fail Rev. 2013 Mar;18(2):107-22. doi: 10.1007/s10741-012-9315-1. Review.

PMID:
22581217
14.

The dilemma, causes and approaches to avoid recurrent hospital readmissions for patients with chronic heart failure.

Zaya M, Phan A, Schwarz ER.

Heart Fail Rev. 2012 May;17(3):345-53. doi: 10.1007/s10741-011-9256-0. Review.

PMID:
21643964
15.

Novel diuretic strategies for the treatment of heart failure in Japan.

Dohi K, Ito M.

Circ J. 2014;78(8):1816-23. Epub 2014 Jul 9. Review.

16.

Epidemiology of heart failure.

Roger VL.

Circ Res. 2013 Aug 30;113(6):646-59. doi: 10.1161/CIRCRESAHA.113.300268. Review.

17.

Determinants of survival following hospitalization for acute heart failure.

Jumean MF, Kiernan MS.

Curr Heart Fail Rep. 2014 Jun;11(2):201-11. doi: 10.1007/s11897-014-0190-z. Review.

PMID:
24477905
18.

The vulnerable phase after hospitalization for heart failure.

Greene SJ, Fonarow GC, Vaduganathan M, Khan SS, Butler J, Gheorghiade M.

Nat Rev Cardiol. 2015 Apr;12(4):220-9. doi: 10.1038/nrcardio.2015.14. Epub 2015 Feb 10. Review.

PMID:
25666406
19.

Heart failure and cognitive impairment: challenges and opportunities.

Heckman GA, Patterson CJ, Demers C, St Onge J, Turpie ID, McKelvie RS.

Clin Interv Aging. 2007;2(2):209-18. Review.

20.

Current evidence of the efficacy of cell-based therapies in heart failure.

Harvey E, Fisher SA, Doree C, Taggart DP, Martin-Rendon E.

Circ J. 2015;79(2):229-36. doi: 10.1253/circj.CJ-14-1415. Epub 2015 Jan 16. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk